ONLINE-ONLY SUPPLEMENTARY MATERIAL

Online-only Tables:

Online-Only Figures:

Supplementary Table 1. Inclusion and exclusion criteria

Inclusion criteria
Visually significant cataract requiring surgery AND Centre-involving diabetic macular oedema (DMO) at baseline OR Centre-involving DMO within 24 months of study enrolment Age more than 18 years
Exclusion criteria
Macular oedema from causes other than diabetic retinopathy OR significant angiographic macular ischaemia Concurrent ocular inflammation / infection Loss of vision from other causes (e.g. age related macular degeneration, myopic macular degeneration) Intractable glaucoma OR pre-existing glaucomatous visual field defect Previous history of steroid response (Intraocular pressure elevation to more than 35mmHg following steroid treatment) Best corrected visual acuity less than 6/60 in the fellow eye Prior history of adverse reaction/allergy to triamcinolone acetate or anti-vascular endothelial growth factor (VEGF) drugs Previous intravitreal injection of triamcinolone acetate within 10 weeks OR intravitreal injection of anti-VEGF drugs within 3 weeks of study entry Previous macular argon laser photocoagulation within 3 months of study entry Patients requiring systemic steroids for other indications (more than 5mg of prednisolone daily or equivalent) Pregnancy OR breastfeeding Patients with concurrent severe systemic infections/disease (e.g. septicaemia)

Supplementary Table 2. Raised IOP during 6 months of study

ID	Group	IOP								Prior IVI	Retreated
		Baseline	Week 1	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6		
A	TA	16	15	19	16	20	**26**	15	**38**	None	Nil
B	TA	13	19	15	DNA	19	**27**	14	16	None	Nil
C	TA	13	12	12	14	14	13	**22**	11	None	Month 6
D	TA	15	**23**	15	14	20	**25**	17	10	None	Nil
E	BVB	19	15	16	16	14	**23**	11	14	1x BVB	Nil
F	BVB	14	19	18	17	13	12	16	**22**	None	Nil
G	BVB	20	10	13	11	14	**23**	18	15	None	Nil

BVB, bevacizumab; **ID**, patient identification; **IOP**, intraocular pressure; **IVI**, previously received intravitreal injections within 24 months prior to study entry/surgery; **TA**, Triamcinolone; **DNA**, patient did not attend that visit



Supplementary Figure 1. Frequency of retreatment required during the first 6 months of the trial

BVB, bevacizumab; **TA**, Triamcinolone.